KRAS and familial pancreatic carcinoma: It also reduces nanoclustering of oncogenic K-Ras that remained at the PM and prevents oncogenic K-Ras signaling and growth of pancreatic cancer cells harboring oncogenic mutant K-Ras but not WT K-Ras.